Factors including age at diagnosis and the specific disease influence the likelihood of children with chronic endocrine conditions being lost to follow-up, show French study findings.
Daily treatment with subcutaneous vosoritide leads to a sustained increase in annualised growth velocity, with generally mild side effects, in children with achondroplasia, show data published in The New England Journal of Medicine.
Researchers advise annual screening for tumours in children with mutations in the SDHB gene, starting from the age of 5 years.
Burosumab treatment improves rickets and prevents decline in growth in young children with X-linked hypophosphataemia, show the findings of an open-label phase II study.
